View in EDS HTML Full Text PDF Full Text

Statins as Immunomodulators in Systemic Sclerosis.

Saved in:
Bibliographic Details
Title: Statins as Immunomodulators in Systemic Sclerosis.
Authors: ABOU‐RAYA, ANNA1 (AUTHOR), ABOU‐RAYA, SUZAN2 (AUTHOR), HELMII, MADIHAH3 (AUTHOR)
Source: Annals of the New York Academy of Sciences. Sep2007, Vol. 1110, p670-680. 11p. 1 Diagram, 2 Charts.
Subjects: Systemic scleroderma, Therapeutics, Immunological adjuvants, Patients, Mortality, Epithelium, Collagen diseases, Blood coagulation factors, Placebos
Abstract: Systemic sclerosis (SSc) has the highest case-specific mortality among the rheumatic diseases. Vascular dysfunction and structural wall abnormalities are among the earliest and fundamental alterations in SSc. Statins have a number of immunomodulating effects on vascular wall cells, which may modify the progression of vascular injury. The aim of this study was to evaluate the potential efficacy of statin therapy in ameliorating endothelial dysfunction (ED) in SSc by investigating the effect of statins on some markers that reflect endothelial activation in SSc. Forty patients with SSc were randomized into two groups to receive 6 months' treatment with atorvastatin ( n= 20; dose, 40 mg/day) or placebo ( n= 20) as an adjuvant to existing therapy. Markers of ED including ET-1, plasma nitrate levels, and thrombomodulin (TM) were evaluated by the enzyme-linked immunosorbent assay (ELISA) technique. Fibrinogen, high-sensitivity C-reactive protein (hsCRP), ESR, lipid peroxide (LP), and malonylaldehyde (MDA) levels were also assessed. Brachial flow-mediated vasodilatation was assessed by ultrasonography. Patients were studied at base line and after 6 months of statin therapy. After 6 months of therapy, ET-1, ICAM-1, sE-selectin, vWF, fibrinogen, ESR, hsCRP as well as LP and MDA levels declined and NO increased significantly in the statin-treated SSc group when compared to the placebo-treated group. Endothelium-dependent vasodilatation (EDV) improved significantly in the atorvastatin-treated group. The findings of this study demonstrated statin-mediated improvements in the endothelial function of SSc patients as well as immunomodulating effects. Statins may thus prove to be an invaluable addition to the therapy of the vasculopathy of SSc. [ABSTRACT FROM AUTHOR]
Copyright of Annals of the New York Academy of Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: egs
DbLabel: Engineering Source
An: 26846841
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Statins as Immunomodulators in Systemic Sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22ABOU‐RAYA%2C+ANNA%22">ABOU‐RAYA, ANNA</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22ABOU‐RAYA%2C+SUZAN%22">ABOU‐RAYA, SUZAN</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22HELMII%2C+MADIHAH%22">HELMII, MADIHAH</searchLink><relatesTo>3</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+the+New+York+Academy+of+Sciences%22">Annals of the New York Academy of Sciences</searchLink>. Sep2007, Vol. 1110, p670-680. 11p. 1 Diagram, 2 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Systemic+scleroderma%22">Systemic scleroderma</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Immunological+adjuvants%22">Immunological adjuvants</searchLink><br /><searchLink fieldCode="DE" term="%22Patients%22">Patients</searchLink><br /><searchLink fieldCode="DE" term="%22Mortality%22">Mortality</searchLink><br /><searchLink fieldCode="DE" term="%22Epithelium%22">Epithelium</searchLink><br /><searchLink fieldCode="DE" term="%22Collagen+diseases%22">Collagen diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+coagulation+factors%22">Blood coagulation factors</searchLink><br /><searchLink fieldCode="DE" term="%22Placebos%22">Placebos</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Systemic sclerosis (SSc) has the highest case-specific mortality among the rheumatic diseases. Vascular dysfunction and structural wall abnormalities are among the earliest and fundamental alterations in SSc. Statins have a number of immunomodulating effects on vascular wall cells, which may modify the progression of vascular injury. The aim of this study was to evaluate the potential efficacy of statin therapy in ameliorating endothelial dysfunction (ED) in SSc by investigating the effect of statins on some markers that reflect endothelial activation in SSc. Forty patients with SSc were randomized into two groups to receive 6 months' treatment with atorvastatin ( n= 20; dose, 40 mg/day) or placebo ( n= 20) as an adjuvant to existing therapy. Markers of ED including ET-1, plasma nitrate levels, and thrombomodulin (TM) were evaluated by the enzyme-linked immunosorbent assay (ELISA) technique. Fibrinogen, high-sensitivity C-reactive protein (hsCRP), ESR, lipid peroxide (LP), and malonylaldehyde (MDA) levels were also assessed. Brachial flow-mediated vasodilatation was assessed by ultrasonography. Patients were studied at base line and after 6 months of statin therapy. After 6 months of therapy, ET-1, ICAM-1, sE-selectin, vWF, fibrinogen, ESR, hsCRP as well as LP and MDA levels declined and NO increased significantly in the statin-treated SSc group when compared to the placebo-treated group. Endothelium-dependent vasodilatation (EDV) improved significantly in the atorvastatin-treated group. The findings of this study demonstrated statin-mediated improvements in the endothelial function of SSc patients as well as immunomodulating effects. Statins may thus prove to be an invaluable addition to the therapy of the vasculopathy of SSc. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Annals of the New York Academy of Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=26846841
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1196/annals.1423.070
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 670
    Subjects:
      – SubjectFull: Systemic scleroderma
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Immunological adjuvants
        Type: general
      – SubjectFull: Patients
        Type: general
      – SubjectFull: Mortality
        Type: general
      – SubjectFull: Epithelium
        Type: general
      – SubjectFull: Collagen diseases
        Type: general
      – SubjectFull: Blood coagulation factors
        Type: general
      – SubjectFull: Placebos
        Type: general
    Titles:
      – TitleFull: Statins as Immunomodulators in Systemic Sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: ABOU‐RAYA, ANNA
      – PersonEntity:
          Name:
            NameFull: ABOU‐RAYA, SUZAN
      – PersonEntity:
          Name:
            NameFull: HELMII, MADIHAH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: Sep2007
              Type: published
              Y: 2007
          Identifiers:
            – Type: issn-print
              Value: 00778923
          Numbering:
            – Type: volume
              Value: 1110
          Titles:
            – TitleFull: Annals of the New York Academy of Sciences
              Type: main
ResultId 1